2026-03-23 17:39:05
Click:
Over the past decade, China's pharmaceutical equipment industry has accelerated its expansion overseas, transitioning from exporting low-end equipment to high-end systematic output, forming a globalized pattern of 'technology + certification + service'. Leading enterprises represented by Tofflon and Truking Technology have made breakthroughs in core equipment technologies such as sterile filling isolators, continuous manufacturing modules, and AI quality control systems, achieving an over 20% improvement in Overall Equipment Effectiveness (OEE). They have also achieved 22 zero-defect certifications from international organizations such as the FDA, CE, and WHO-GMP, breaking the 20-year market monopoly of European and American enterprises. The export market has rapidly expanded from emerging regions such as Southeast Asia and Central Asia to high-end markets in Europe and America. Mechanisms such as the China-ASEAN Centralized Procurement Platform and Xinjiang-Central Asia Pharmacies have driven significant growth in orders. In 2024, the export value of pharmaceutical products reached US$107.964 billion, with high-end equipment accounting for an increasing proportion. The enterprise's overseas expansion model has evolved from 'selling equipment' to 'exporting standards and solutions'. Truking Technology acquired Romaco of Germany to establish a dual R&D headquarters in China and Germany, while Tofflon's filling lines have entered the supply chains of over 2,000 pharmaceutical companies worldwide. Companies such as Tailin Biotechnology and Qilu Pharmaceutical have deepened ecological collaboration through CMO cooperation and international exhibitions. As innovative drugs expand overseas, driving industrial chain linkage, China's pharmaceutical equipment is transitioning from 'Made in China' to 'Intelligent Manufacturing in China', becoming a key node in the global pharmaceutical supply chain.